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Abstract: Background: A meta-analysis was conducted to summarize the evidence from prospective
cohort and case-control studies regarding the association between coffee intake and biliary tract
cancer (BTC) and liver cancer risk. Methods: Eligible studies were identified by searches of
PubMed and EMBASE databases from the earliest available online indexing year to March 2017.
The dose–response relationship was assessed by a restricted cubic spline model and multivariate
random-effect meta-regression. A stratified and subgroup analysis by smoking status and hepatitis
was performed to identify potential confounding factors. Results: We identified five studies on BTC
risk and 13 on liver cancer risk eligible for meta-analysis. A linear dose–response meta-analysis did
not show a significant association between coffee consumption and BTC risk. However, there was
evidence of inverse correlation between coffee consumption and liver cancer risk. The association
was consistent throughout the various potential confounding factors explored including smoking
status, hepatitis, etc. Increasing coffee consumption by one cup per day was associated with a 15%
reduction in liver cancer risk (RR 0.85; 95% CI 0.82 to 0.88). Conclusions: The findings suggest that
increased coffee consumption is associated with decreased risk of liver cancer, but not BTC.
Keywords: coffee; caffeine; gallbladder cancer; biliary tract cancer; liver cancer; hepatitis;
meta-analysis; dose–response
1. Introduction
Coffee is one of the most consumed beverages worldwide and it has been associated with a
number of benefits on human health including a decreased risk of all-cause, cardiovascular, and cancer
mortality [1–3]. Coffee is composed of a variety of compounds, some of which have been reported to
have an impact on liver health [4]. Caffeine, a major component in coffee has been proposed to exert
anti-carcinogenic effects toward up-regulation of antioxidant-responsive element (ARE)-mediated
signalling [5], while phenolic compounds in coffee have been shown to exert anti-oxidant and
anti-inflammatory effects [6]. In addition, coffee diterpenes have potential anti-carcinogenic effects [6].
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However, besides the contribution of individual compounds or groups of compounds to liver health,
synergistic effects are also possible.
Gallbladder (GB) cancer is a highly fatal malignancy with notable geographical variations and a
higher incidence in women. The aetiology of biliary tract cancer (BTC), including GB cancer and bile
duct cancer (BDC) is poorly understood. One of the main risk factors has been hypothesized to be
prolonged exposure to gallstones associated with chronic inflammation [7], which may increase the risk
of BTC [8]. It has also been suggested that dietary factors contributing to gallstone formation can play a
role in aetiology of BTC. Caffeinated and decaffeinated coffee consumption stimulates cholecystokinin
release, which in turn stimulates the smooth muscle of gallbladder, causing its contraction [9]. However,
gallbladder contraction may cause pain/colics in patients with gallstones. Moreover, coffee intake
decreases cholesterol crystallization in bile, preventing gallstone formation [10] and modulating
inflammation associated with the presence of gallstones [7].
Among the main targets of the healthful effects of coffee, the liver in particular, appears to benefit
from coffee consumption due to the improvement of lipid metabolism regulation and decreased rates
of liver steatosis and non-alcoholic steatohepatitis, which in turn may decrease the risk of consequent
inflammation and fibrosis [11]. A recent systematic review showed that coffee consumption was
consistently associated with lower rates of chronic liver disease and cirrhosis [12]. Interestingly, several
studies have examined the impact of coffee consumption on fibrosis severity in patients with chronic
viral hepatitis and have shown decreased rates of liver disease progression in coffee drinkers [13].
Recently, meta-analyses on coffee consumption and liver cancer risk have been published [14,15], but
they lacked data on BTC risk, dose–response analyses, or analysis of possible confounding factors.
The aim of the present study was to perform a meta-analysis of observational studies on coffee
consumption and liver and BTC cancers, including the dose–response relation while taking into
account the role of several potential confounding factors.
2. Materials and Methods
Meta-Analysis of Observational Studies in Epidemiology (MOOSE) protocols were followed
throughout design, execution, analysis and reporting of this meta-analysis (Table S1) [16].
2.1. Search Strategy
We conducted a comprehensive literature search using PubMed (http://www.ncbi.nlm.nih.gov/
pubmed/) and EMBASE (http://www.embase.com/) databases from the earliest available online
indexing year to March 2017, with English-language restriction. Search terms included the following:
(coffee OR caffeine OR beverages) and (extrahepatic OR gallbladder OR biliary tract OR liver OR
hepatocellular) and (cancer OR carcinoma OR neoplasm) (Table S2). Two authors separately screened
and retrieved the studies. We included prospective and case-control studies that evaluated association
between dietary coffee intake and risk of extrahepatic/hepatic cancer in generally healthy adults.
Studies were included if they provided corresponding risk estimates such as RRs (Risk Ratios), HRs
(Hazard Ratios), or ORs (Odds Ratios). We excluded studies that reported insufficient statistics or
insufficient coffee consumption categories (less than three; Table S3). Reference lists of included
manuscripts were also examined for additional studies not previously identified. When duplicate
publications from the same study were identified, we included the report that provided the largest
number of cases/entire cohort or with the longest follow-up for each endpoint of interest. Full-texts of
potentially relevant articles were assessed independently for eligibility by two authors.
2.2. Data Extraction
Data were abstracted from each identified study using a standardized extraction form.
The following information was collected: (1) first author name; (2) year of publication; (3) study
cohort name; (4) country; (5) number of participants; (6) sex of participants; (7) age range of the study
population at baseline; (8) categories of consumption; (9) follow-up period; (10) endpoints and cases;
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(11) distributions of cases and person-years, HRs, and 95% CIs for all categories of exposure; and
(12) covariates used in adjustments. This process was performed independently by two authors and
discrepancies were discussed and resolved by consensus. The quality of included studies was assessed
according to the Newcastle–Ottawa Quality Assessment Scale [17], which consists of three variables
of quality as follows, selection (4 points), comparability (2 points), and outcome (3 points), for a total
score of 9 points (9 representing the highest quality).
2.3. Statistical Analysis
In this meta-analysis, ORs and HRs were deemed equivalent to relative risks (RRs) [18]. ORs, RRs
and HRs with 95% CI for all categories of exposure were extracted for the analysis and random-effects
models were used to calculate pooled RR with 95% CI for the highest versus lowest category
of exposure. The highest versus lowest analysis was performed to determine the relationship
between coffee intake and risk of BTC and liver cancer. We included gallbladder cancer and
extrahepatic/intrahepatic bile duct cancer in the same analysis, as their aetiology is similar [7]. The risk
estimate from the most fully adjusted models in the analysis of the pooled RR was used. Heterogeneity
was assessed using the Q test and I2 statistic. The level of significance equal to 0.10 was used
for the Q test. The I2 statistic represented the amount of total variation that could be attributed
to heterogeneity. I2 values ≤25%, 25–50%, 50–75%, and >75% indicated no, small, moderate, and
significant heterogeneity, respectively. A sensitivity analysis by exclusion of one study at a time
was performed to evaluate the stability of results and potential sources of heterogeneity. Subgroup
analysis was only performed for liver cancer risk, in order to check for potential source of heterogeneity
according to study design, gender and geographical area. To test for potential confounders/effect
modifiers, subgroup analyses were performed according to smoking status, coffee type and hepatitis.
Publication bias was evaluated by a visual investigation of funnel plots for potential asymmetry.
A dose–response analysis was performed using the method of Greenland and Longnecker to
calculate study-specific liner and non-linear trend (generalized least-squares, GLS) based on results
across categories of coffee intake [19,20]. Data were extracted on the level of coffee intake, distributions
of cases and person-years (when available), and ORs/RRs/HRs with 95% CIs for ≥3 exposure
categories. The median or mean intake of coffee in each category was assigned to the corresponding
OR/RR/HR with the 95% CI for each study. When coffee consumption was reported in a range
of intake, the midpoint of the range was used. When the highest category was open ended, we
assumed the width of the category to be the same as the adjacent category. When the lowest category
was open ended, we set the lower boundary to zero. Two-stage random-effects dose–response
meta-analysis was performed to examine linear and non-linear relationship between coffee intake
and risk of biliary tract cancer and liver cancer. In the first stage the method of Greenland and
Longnecker (generalized least-squares, GLS) was used to calculate study-specific coefficients on the
basis of results across categories of coffee intake taking into account the correlation within each
set of retrieved ORs/RRs/HRs [19,20]. Non-linear dose–response analysis was modelled using
restricted cubic splines with 3 knots at fixed percentiles (25%, 50%, and 75%) of the distribution [21].
The coefficients that had been estimated within each study by performing random-effects meta-analysis
were combined. In linear dose–response meta-analysis the method of DerSimonian and Laird was
used and in non-linear dose–response meta-analysis the multivariate extension of the method of
moments was used to estimate the relative risks. We calculated an overall P-value by testing that
the 2 regression coefficients were simultaneously equal to zero. We then calculated a P-value for
non-linearity by testing that the coefficient of the second spline was equal to zero. All analyses were
performed with R software Version 3.0.3, using dosresmeta and mvmeta packages (Development Core
Team, Vienna, Austria).
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3. Results
3.1. Study Characteristics
The study selection process of eligible studies is presented in Figure 1. For the analysis
on the association between coffee consumption and BTC risk five studies were eligible [22–26],
one of which was a pooling project of nine cohort studies [25], two were studies comprising three
prospective cohorts [23,24], and two were case-control studies [22,26]. Eligible studies included
1,375,626 participants and 726 BTC cases. The main characteristics of the studies included in
the meta-analysis are summarized in Table 1. Six studies provided data for men and women
separately [25,27–31]. Four studies provided data on type of coffee consumed [25,32–34], six on
smoking status [25,27,28,30,31,35], and six on hepatitis [27,29,30,33,36,37]. Three studies were
conducted in USA [22,25,26], one in Europe [23] and one in Asia [24]. The follow-up in prospective
cohort studies ranged from about 13 to 20 years, and the age range at study baseline was 30–84 years.
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Table 1. Characteristics of the studies included in the meta-analysis.
Author, Year Cohort Name, Country Years of Study,Follow-up
Cases; Controls/Total
Population Age Range, Gender Adjustments
Biliary Tract Cancer
Prospective
Petrick, 2015 LCPP, USA Multicentre 260; 1,212,893 MF Age, sex, race, cohort, BMI, smoking status, cigarette smokingintensity, alcohol.
Makiuchi, 2016 JPHC, Japan
1990–2010 Cohort I,
1993–2010 Cohort II,
20 years (maximum)
Cohort I, 17 years
(maximum) Cohort II
267; 89,555 40–69 years, MF
Age, sex, study area, BMI, history of cholelithiasis, history of
diabetes mellitus, history of chronic hepatitis or cirrhosis,
history of smoking, drinking frequency, physical activity by
METs/day score, total energy consumption, energy-adjusted
consumption of fish, red meat, and vegetable and fruit, and
green tea.
Larsson, 2017 SMC, COSM, Sweden 1998–2012, 13.3 years 74; 72,680 45–83 years, MF Age, sex, education, smoking, BMI, and diabetes.
Case-Control
Yen, 1987 USA 1975–1979, NA 67/272 50–79 years, MF Sex and age in decades.
Chow, 1994 USA 1985–1989, NA 98/226 30–84 years, MF Age, ethnic origin, and smoking status.
Liver Cancer
Prospective
Inoue, 2005 JPHC, Japan
1990–2001 Cohort I,
1993–2001 Cohort II,
9.7 years (average)
334; 90,452 40–69 years, MF Sex, age, study area, tobacco-smoking status, ethanol intake,green vegetable intake, green tea drinking.
Hu, 2008 Finland 1972–2002, 19.3 years(average) 128; 60,323 25–74 years, MF
Age, sex, study year, alcohol consumption, education, smoking,
diabetes and chronic liver disease at baseline and during
follow-up, and BMI.
Inoue, 2009 JPHC, Japan 1993–2006 Cohort II,12.7 years (average) 110; 18,815 40–69 years, MF
Sex, age, area, smoking status, weekly ethanol intake, BMI,
history of diabetes mellitus, green tea consumption, serum ALT
level, HCV infection status, and HBV infection status.
Johnson, 2011 SCHS, China 1993–2006, 13 years(maximum) 362; 61,321 45–74 years, MF
Age at recruitment, gender, dialect group, year of recruitment,
BMI, level of education, consumption of alcoholic beverages,
cigarette smoking, frequency of black tea and green tea intake,
history of diabetes.
Lai, 2013 ATBC, Finland 1994–2009, 18.2 years(median) 194; 27,037 ~57 years (median), M
ATBC intervention arm, age, BMI, education, marital status,
history of diabetes, years of smoking, cigarettes smoked per
day, alcohol, tea intake, and serum cholesterol.
Bamia, 2015 EPIC, Multicentre Europe 1992–2010, 11 years(median) 201; 486,799 25–70 years, MF
Age at recruitment, centre, sex, diabetes mellitus, education,
BMI, smoking, physical activity, alcohol intake, energy intake,
simultaneously including tea.
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Table 1. Cont.
Author, Year Cohort Name, Country Years of Study,Follow-up
Cases; Controls/Total
Population Age Range, Gender Adjustments
Petrick, 2015 LCPP, USA
Consortium (AARP, AHS,
USRT, PLCO, WHS, CPSII,
IWHS, BWHS, WHI)
860; 1,212,893 MF Sex, age, race, cohort, BMI, smoking status, cigarette smokingintensity, alcohol.
Setiawan, 2015 MEC, USA 1993–2010, 18 years(median) 451; 162,022 45–75 years, MF
Age, sex, and race/ethnicity, education, BMI, alcohol intake,
smoking status, and diabetes.
Case-Control
Gallus, 2002 Greece, Italy
I study (Italy) 1984–1997,
II study (Greece)
1995–1998, NA
333/360 Greece;
501/1552 Italy 20–79 years, MF
Age, sex, smoking, tobacco smoking, alcohol drinking, BMI,
history of diabetes and hepatitis.
Gelatti, 2005 Italy 1994–2003, NA 250/500 50–79 years, MF HBV infection, HCV infection, alcohol intake, sex and age.
Montella, 2007 Italy 1999–2002, NA 185/412 43–84 years, MF
Gender, age, centre, education, smoking habits, maximal
lifetime alcohol intake and serological evidence of HCV and/or
HBV infection.
Tanaka, 2007 Japan 2001–2004, NA 209/1308 40–79 years, MF Sex, age, heavy alcohol use and smoking status.
Leung, 2011 China 2007–2008, NA 109/125 MF Age, gender, cigarette smoking, alcohol use, tea consumption,physical activity.
Abbreviations: AARP: (American Association of Retired Persons) Diet and Health Study; AHS: Agricultural Health Study; ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention
ATBC Study; BWHS: Black Women’s Health Study; COSM: Cohort of Swedish Men; CPSII: Cancer Prevention Study II; EPIC: European Prospective Investigation into Cancer and
Nutrition; IWHS: Iowa Women’s Health Study; JPHC: Japan Public Health Center-based Prospective Study; LCPP: Liver Cancer Pooling Project; MEC: Multiethnic Cohort Study; PLCO:
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SCHS: Singapore Chinese Health Study; SMC: The Swedish Mammography Cohort; USRT: U.S. Radiologic Technologists
(USRT) Cohort; WHI: Women’s Health Initiative; WHS: Women’s Health Study.
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Thirteen studies [25,27–38], including seven studies on six prospective cohorts and one multicentre
study (EPIC) [28–32,34,38], one pooling project of nine prospective cohorts [25], and five case-control
studies [27,33,35–37], were eligible for the analysis on the association between coffee consumption
and liver cancer. Eligible studies included 2,105,104 individuals and 4227 liver cancer cases. The main
characteristics of the studies included in the meta-analysis are summarized in Table 1. Two studies
were conducted in USA [25,34], six in Europe [27,28,31–33,36], and five in Asia [29,30,35,37,38].
The follow-up in prospective cohort studies ranged from about 9 to 19 years, and the age range
at study baseline was 20–79 years.
3.2. Summary Relative Risk for the Highest versus Lowest Category of Coffee Consumption
The summary RR of BTC for the highest versus lowest category of coffee consumption was 0.83,
95% CI: 0.64, 1.08, with no evidence of heterogeneity I2 = 0%, p = 0.58 (Figure 2). No publication bias
was found after visual inspection of funnel plot (Figure S1). The pooled estimations were RR = 0.84,
95% CI: 0.61, 1.15; I2 = 22%, p = 0.27 for prospective cohort studies, and RR = 0.74, 95% CI: 0.34, 1.63;
I2 = 0%, p = 0.82 for case-control studies (Figure 2). The subgroup analysis was not performed due to
the limited number of studies eligible for the meta-analysis.
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Figure 2. Forest plot of summary relative risks (RRs) of BTC for the highest versus lowest (reference)
category of coffee consumption, by study design.
The summary RR of liver cancer for the highest versus lowest category of coffee consumption
was RR = 0.52, 95% CI: 0.42, 0.63 with moderate heterogeneity I2 = 44%, p = 0.02, (Figure 3). However,
no publication bias was found after visual inspection of funnel plot (Figure S2). The summary RR in
separate analysis for prospective cohort studies was RR = 0.53, 95% CI: 0.41, 0.69; I2 = 46%, p = 0.03,
and RR = 0.48, 95% CI: 0.33, 0.70; I2 = 47%, p = 0.08 for case-control studies (Figure 3).
When considering sex and smoking status, no significant differences in comparison to main
analysis of prospective cohorts were found (Table 2). In contrast, a significant decrease in risk of liver
cancer for caffeinated coffee (RR = 0.65, 95% CI: 0.49, 0.86; I2 = 0%, p = 0.59), but not for decaffeinated
(RR = 0.85, 95% CI: 0.63, 1.14; I2 = 0%, p = 0.96) was found (Table 2). In the stratified analysis, a lower
risk of liver cancer was found among studies conducted in European and Asian countries compared
to USA, even though all results were statistically significant (Table 2). Finally, stratified analysis by
chronic hepatitis status did not significantly alter the results (Table 2).
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Figure 3. Forest plot of summary relative risks (RRs) of liver cancer for the highest versus lowest
(reference) category of coffee consumption, by study design.
Table 2. Subgroup analyses of studies reporting risk of liver cancer for the highest versus lowest
(reference) category of coffee consumption.
Liver Cancer
Subgroup No. of Datasets RR (95% CI) I2 Pheterogeneity
Total 20 0.52 (0.42, 0.63) 44% 0.02
Study design
Prospective 13 0.53 (0.41, 0.69) 46% 0.03
Case-control 7 0.48 (0.33, 0.70) 47% 0.08
Gender
Men
Prospective 5 0.49 (0.30, 0.80) 64% 0.02
Case-control 1 0.60 (0.40, 0.80) NA NA
Women
Prospective 4 0.53 (0.33, 0.83) 0% 0.71
Case-control 1 0.70 (0.50, 0.90) NA NA
Geographical location
North America 4 0.72 (0.52, 0.98) 42% 0.16
Asia 7 0.42 (0.30, 0.58) 10% 0.35
Europ 9 .48 (0.36, 0.64) 35% 0.14
Coffee type
Caffeinated 3 0.65 (0.49, 0.86) 0% 0.59
Decaffeinated 4 0.85 (0.63, 1.14) 0% 0.96
Smoking status
Never/former smoker 4 0.61 (0.43, 0.88) 32% 0.22
Current smoker 5 0.54 (0.36, 0.81) 61% 0.04
Chronic hepatitis
Yes 7 0.56 (0.39, 0.80) 0% 0.87
No 5 0.60 (0.48, 0.75) 0% 0.71
Nutrients 2017, 9, 950 9 of 17
3.3. Dose–Response Meta-Analysis
Three studies [23–25] were eligible for dose–response meta-analysis of prospective cohort studies
on coffee consumption and BTC risk. In both non-linear and linear dose–response meta-analysis no
significant association between coffee consumption and BTC risk was apparent (Figure 4, Table 3).
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Figure 4. ose–response association between coffee consumption and BTC risk (a) non-linear; (b) linear.
Solid lines represent relative risk, dashed lines represent 95% confidence intervals.
For the dose–response analysis on the association between coffee consumption and liver cancer
risk, seven studies were eligible [25,28–30,32,34,38]. We found an evidence of linear association
between coffee consumption and liver cancer risk (Pfor nonlinearity = 0.954) (Figure 5, Table 4). Compared
with no coffee consumption, the pooled relative risks for liver cancer were: 0.82, 95% CI: 0.70, 0.98 for
one cup/day; 0.68, 95% CI: 0.53, 0.88 for two cups/day; 0.57, 95% CI: 0.46, 0.70 for three cups/day;
0.47, 95% CI: 0.39, 0.56 for four cups/day; 0.39, 95% CI: 0.31, 0.50 for five cups/day; 0.33, 95% CI: 0.23,
0.46 for six cups/day; and 0.27, 95% CI: 0.17, 0.43 for seven cups/day. The associations were similar
for men and women, although, in the analysis for women, a higher heterogeneity (Pheterogeneity = 0.692)
was observed.
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Table 3. Dose–response meta-analysis of prospective cohort studies on coffee consumption and biliary tract cancer risk.
No. of Datasets
(No. of Studies)
Coffee Intake (Cups/Day)
I2 (%) Pheterogeneity Pnon-linearity
0 1 2 3 4 5 6 7
Total analysis
Non-linear 3 (3) Reference 0.84 (0.67, 1.05) 0.77 (0.54, 1.10) 0.77 (0.43, 1.38) 0.77 (0.31, 1.91) 0.77 (0.22, 2.70) 0.77 (0.15, 3.86) 0.77 (0.11, 5.54) 0.54 0.15 0.46
Linear 3 (3) Reference 0.91 (0.80, 1.03) 0.82 (0.64, 1.06) 0.75 (0.51, 1.09) 0.68 (0.41, 1.12) 0.61 (0.33, 1.15) 0.56 (0.26, 1.18) 0.50 (0.21, 1.22) 0.18 0.13 NA
Table 4. Dose–response meta-analysis of prospective cohort studies on coffee consumption and liver.
No. of Datasets
(No. of Studies)
Coffee Intake (Cups/Day)
I2 (%) Pheterogeneity Pnon-linearity
0 1 2 3 4 5 6 7
Total analysis
Non-linear 7 (6) Reference 0.82 (0.70, 0.98) 0.68 (0.53, 0.88) 0.57 (0.46, 0.7) 0.47 (0.39, 0.56) 0.39 (0.31, 0.5) 0.33 (0.23, 0.46) 0.27 (0.17, 0.43) 54.18 0.010 0.954
Linear 7 (6) Reference 0.85 (0.82, 0.88) 0.72 (0.66, 0.78) 0.61 (0.54, 0.69) 0.52 (0.44, 0.61) 0.44 (0.36, 0.54) 0.58 (0.34, 0.98) 0.32 (0.24, 0.42) 17.54 0.296 NA
Male
Non-linear 5 (5) Reference 0.73 (0.57, 0.94) 0.56 (0.36, 0.85) 0.47 (0.30, 0.72) 0.42 (0.29, 0.60) 0.38 (0.27, 0.53) 0.33 (0.23, 0.46) 0.30 (0.19, 0.48) 72.9 0.000 0.286
Linear 4 (4) Reference 0.84 (0.80, 0.89) 0.71 (0.64, 0.79) 0.60 (0.51, 0.71) 0.51 (0.41, 0.63) 0.43 (0.33, 0.56) 0.55 (0.47, 0.63) 0.31 (0.21, 0.44) 15.48 0.314 NA
Female
Non-linear 4 (4) Reference 0.87 (0.72, 1.06) 0.76 (0.56, 1.03) 0.65 (0.46, 0.92) 0.56 (0.31, 1.01) 0.48 (0.19, 1.22) 0.32 (0.22, 0.49) 0.35 (0.06, 1.90) 0 0.586 0.938
Linear 3 (3) Reference 0.88 (0.80, 0.96) 0.77 (0.65, 0.92) 0.68 (0.52, 0.88) 0.59 (0.42, 0.84) 0.52 (0.34, 0.81) 0.53 (0.44, 0.65) 0.40 (0.22, 0.74) 0 0.692 NA
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Figure 5. Dose–response association between coffee consumption and liver cancer risk: (a) non-linear,
total analysis; (b) linear, total analysis; (c) non-linear, male; (d) linear, male; (e) non-linear,
female; and (f) linear, female. Solid lines represent relative risk, while dashed lines represent 95%
confidence intervals.
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4. Discussion
In the present meta-analysis, the inverse association between coffee consumption and risk of liver
cancer was consistent when taking into account key potential confounding factors. In contrast,
no significant association between coffee consumption and risk of BTC was evident. Notably,
a non-significant decreased risk was found especially for lower intake of coffee (i.e., two cups/day);
however, higher intake was associated with no further benefit or rather an increased risk in two out of
the three cohorts examined. Furthermore, the limited number of the studies eligible for meta-analysis
is not sufficient to draw conclusions on the association between coffee consumption and BTC risk.
From a mechanistic point of view, intake of both caffeinated and decaffeinated coffee stimulates
gallbladder contraction caused by increased concentration in plasma cholecystokinin induced by coffee
and decreases gallbladder volume by approximately 30% [9]. Furthermore, coffee can exert a protective
effect on gallbladder by decreasing the crystallization of cholesterol in bile [10]. However, induction of
gallbladder contraction in patients with gallstones may induce the passage of gallstones to bile duct [7].
Overall, whilst a rationale for potential benefit exists, findings to date do not support such hypotheses.
A possible reason for heterogeneity between results could depend on the different population involved
that may have different health risk behaviours. For instance, higher intake of coffee was relatively
poorly associated with alcohol consumption in the Northern European cohorts [39], which showed a
decreased risk of BTC. In contrast, coffee was associated with higher alcohol intake in Asian [40] and
US cohorts [41–45], which reported no benefits of coffee consumption on BTC risk. However, current
data are not sufficient to reach final conclusions and further investigations are needed to clarify the
relation between coffee consumption and BTC taking into account potential confounders.
Findings on coffee consumption and liver cancer risk were more consistent: all sensitivity and
subgroup analyses performed showed significant decreasing risk of cancer with a linear dose–response
relation. Molecular targets involved in the chemopreventive effects of coffee include the nuclear factor
E2-related factor 2 (Nrf2), responsible for transcription of enzymes involved in detoxification processes
and in cellular antioxidant defences [46]: a diet rich in coffee has been demonstrated to increase
gene expression of NAD(P)H: quinone oxidoreductase 1, glutathione S-transferase class Alpha 1,
UDP-glucuronosyl transferase 1A6, and the glutamate cysteine ligase catalytic subunit, all involved in
the antioxidant response of the organism [47]. With special regard to hepatocellular carcinoma, coffee
decreased the incidence of liver tumours in rats [48], reduced the numbers of hyperplastic liver cell
foci in chemical models of colon and liver cancer [49], and reduced solid tumour growth, proliferation,
and hepatoma metastases [50,51].
A number of experimental studies provided the biological rationale for the components
responsible for beneficial effects of coffee on liver cells. In this meta-analysis, a significant decrease
in risk of liver cancer for caffeinated coffee, but not for decaffeinated, was found. Caffeine has
been reported to reduce fibrosis in in vitro and animal studies, inhibiting TGF-beta-induced CTGF
(Connective Tissue Growth Factor) expression in hepatocytes by stimulation of degradation of
the TGF-beta effector SMAD 2, inhibition of SMAD3 phosphorylation and up-regulation of the
PPARgamma-receptor [52,53], as well as increased activity of superoxide dismutase and catalase
in the liver and increased expression of Nrf2 [54].
It has been shown that the caffeine metabolite paraxanthine may be responsible for the
down-regulation of the expression of the fibrogenic protein CTGF in hepatic stellate cells and reduction
of liver fibrosis and lipid peroxidation [55]. More recent investigations have shown that caffeine is
not essential for the anti-fibrotic effects of coffee. It has been demonstrated in animal studies that
both caffeinated and decaffeinated coffee reduce liver fibrosis and TGF-beta expression [56,57] and
that use of decaffeinated coffee is able itself to reduce liver steatosis, inflammation and fibrosis in
animal models [58]. The phenolic compounds chlorogenic acids and caffeic acid are among the main
candidates for the antioxidant effects of coffee on liver. Chlorogenic acids administration, or treatment
in animal studies, reduces liver fibrosis through decreased expression of collagen I and collagen III,
as well as reducing the expression of inflammatory cytokines, TLR4, myeloid differentiation factor 88,
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inducible nitric oxide synthase and cyclooxygenase-2 and nuclear factor-κB activation [59–61]. Caffeic
acid reduces liver fibrosis due to its ability to suppress the activation of hepatic stellate cells by
inhibiting oxidative stress through decrease of Keap1 expression, inhibition of Keap1 and Nrf2 binding,
and thus activating Nrf2 and leading to increased expression of antioxidative signals [62–64]. Finally,
coffee consumption may exert indirect protective effects on the liver due to the potential improvements
of metabolism [3]. Coffee consumption has been inversely associated in several studies to metabolic
syndrome [65–74], which has been related to liver fat accumulation and liver impairment due to
common pathogenic determinants, such as insulin resistance and oxidative stress; impaired metabolism
may induce progressive liver damage, liver inflammation and fibrosis, which ultimately may lead to
carcinogenic transformation [75].
The results of the present study should be considered in the light of a number of limitations. First,
some analyses reported moderate heterogeneity. As previously mentioned, several factors may explain
differences across studies, including type of coffee bean (Arabica or Robusta), roasting, and beverage
preparation. Secondly, genetic variants associated with caffeine metabolism are not considered in
prospective cohort studies but were included in the meta-analysis and may contribute to the observed
heterogeneity. Coffee consumption was assessed before outcome, thus recall bias is unlikely. However,
misclassification of the actual amounts consumed may have affected the dose–response relation.
Reverse causation may have affected the results if individuals changed coffee intake due to a diagnosed
medical condition or disease; however, any such effects would be muted in studies with a long duration.
5. Conclusions
In conclusion, coffee may represent a valid functional food for liver protection. Current evidence is
sufficient to guide future clinical randomized trials to test the hepatoprotective effects of coffee, which
in turn may lead to more definitive recommendations. However, further observational studies with
better in depth analyses of potential confounding factors are needed to test the association between
coffee consumption and BTC.
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